Complete response and prolonged disease-free survival in a patient with recurrent duodenal adenocarcinoma treated with bevacizumab plus FOLFOX6

Gayathri Nagaraj; Yousef Zarbalian; Karin Flora; Benjamin R. Tan

doi:10.3978/j.issn.2078-6891.2013.038

Complete response and prolonged disease-free survival in a patient with recurrent duodenal adenocarcinoma treated with bevacizumab plus FOLFOX6

Gayathri Nagaraj, Yousef Zarbalian, Karin Flora, Benjamin R. Tan

Research output: Contribution to journal › Article › peer-review

7 Scopus citations

Abstract

Small bowel adenocarcinoma is an uncommon gastrointestinal malignancy with limited data on effective chemotherapy in the adjuvant setting, as well as for advanced disease. We present a case report of a patient with recurrent duodenal adenocarcinoma after resection and adjuvant chemotherapy who experienced a complete response to bevacizumab with oxaliplatin and 5FU (FOLFOX) followed by bevacizumab/capecitabine maintenance therapy for 2 years. The patient continues to be disease-free 8 years after his recurrence. This case highlights the potential of vascular endothelial growth factor (VEGF) inhibitors to enhance chemotherapeutic regimens for advanced small bowel adenocarcinoma.

Original language	English
Pages (from-to)	E1-E6
Journal	Journal of Gastrointestinal Oncology
Volume	5
Issue number	1
DOIs	https://doi.org/10.3978/j.issn.2078-6891.2013.038
State	Published - Feb 2014

Keywords

Bevacizumab
Capecitabine
Oxaliplatin
Small bowel adenocarcinoma

Access to Document

10.3978/j.issn.2078-6891.2013.038

Cite this

@article{f8acf28e2f864570aee9755f63e4be3f,

title = "Complete response and prolonged disease-free survival in a patient with recurrent duodenal adenocarcinoma treated with bevacizumab plus FOLFOX6",

abstract = "Small bowel adenocarcinoma is an uncommon gastrointestinal malignancy with limited data on effective chemotherapy in the adjuvant setting, as well as for advanced disease. We present a case report of a patient with recurrent duodenal adenocarcinoma after resection and adjuvant chemotherapy who experienced a complete response to bevacizumab with oxaliplatin and 5FU (FOLFOX) followed by bevacizumab/capecitabine maintenance therapy for 2 years. The patient continues to be disease-free 8 years after his recurrence. This case highlights the potential of vascular endothelial growth factor (VEGF) inhibitors to enhance chemotherapeutic regimens for advanced small bowel adenocarcinoma.",

keywords = "Bevacizumab, Capecitabine, Oxaliplatin, Small bowel adenocarcinoma",

author = "Gayathri Nagaraj and Yousef Zarbalian and Karin Flora and Tan, {Benjamin R.}",

year = "2014",

month = feb,

doi = "10.3978/j.issn.2078-6891.2013.038",

language = "English",

volume = "5",

pages = "E1--E6",

journal = "Journal of Gastrointestinal Oncology",

issn = "2078-6891",

number = "1",

}

TY - JOUR

T1 - Complete response and prolonged disease-free survival in a patient with recurrent duodenal adenocarcinoma treated with bevacizumab plus FOLFOX6

AU - Nagaraj, Gayathri

AU - Zarbalian, Yousef

AU - Flora, Karin

AU - Tan, Benjamin R.

PY - 2014/2

Y1 - 2014/2

N2 - Small bowel adenocarcinoma is an uncommon gastrointestinal malignancy with limited data on effective chemotherapy in the adjuvant setting, as well as for advanced disease. We present a case report of a patient with recurrent duodenal adenocarcinoma after resection and adjuvant chemotherapy who experienced a complete response to bevacizumab with oxaliplatin and 5FU (FOLFOX) followed by bevacizumab/capecitabine maintenance therapy for 2 years. The patient continues to be disease-free 8 years after his recurrence. This case highlights the potential of vascular endothelial growth factor (VEGF) inhibitors to enhance chemotherapeutic regimens for advanced small bowel adenocarcinoma.

AB - Small bowel adenocarcinoma is an uncommon gastrointestinal malignancy with limited data on effective chemotherapy in the adjuvant setting, as well as for advanced disease. We present a case report of a patient with recurrent duodenal adenocarcinoma after resection and adjuvant chemotherapy who experienced a complete response to bevacizumab with oxaliplatin and 5FU (FOLFOX) followed by bevacizumab/capecitabine maintenance therapy for 2 years. The patient continues to be disease-free 8 years after his recurrence. This case highlights the potential of vascular endothelial growth factor (VEGF) inhibitors to enhance chemotherapeutic regimens for advanced small bowel adenocarcinoma.

KW - Bevacizumab

KW - Capecitabine

KW - Oxaliplatin

KW - Small bowel adenocarcinoma

UR - http://www.scopus.com/inward/record.url?scp=84995740354&partnerID=8YFLogxK

U2 - 10.3978/j.issn.2078-6891.2013.038

DO - 10.3978/j.issn.2078-6891.2013.038

M3 - Article

C2 - 24490045

AN - SCOPUS:84995740354

SN - 2078-6891

VL - 5

SP - E1-E6

JO - Journal of Gastrointestinal Oncology

JF - Journal of Gastrointestinal Oncology

IS - 1

ER -

Complete response and prolonged disease-free survival in a patient with recurrent duodenal adenocarcinoma treated with bevacizumab plus FOLFOX6

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this